Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Fell 12.6% in March

By Keith Noonan – Updated Apr 7, 2021 at 8:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech was under pressure last month, but it's bouncing back in April.

What happened

Shares of Illumina (ILMN 0.89%) dipped 12.6% in March, according to data from S&P Global Market Intelligence. The stock lost ground due to negative analyst coverage and a challenge to its acquisition of liquid-biopsy specialist Grail.

ILMN Chart

ILMN data by YCharts

Barclays analyst Luke Sergott published a note initiating coverage on Illumina stock on March 2. The analyst gave an underweight rating to the biotech stock and set a one-year price target of $325 per share, suggesting roughly 27% downside at the time of the note's publication.

A DNA strand.

Image source: Getty Images.

So what

The Barclays note on Illumina stock acknowledged that the company has a significant opportunity in gene sequencing and management, but indicated that it would face near-term growth issues and was likely overvalued as a result. The coverage corresponded with a significant pullback for the genetics specialist's share price, and the stock's valuation was put under additional pressure at the end of the month after the Federal Trade Commission announced it was challenging the company's planned $7.1 billion acquisition of Grail. 

Now what

Illumina stock has gained ground early in April. The price is up roughly 8% in the month so far thanks to encouraging preliminary first-quarter results. 

ILMN Chart

ILMN data by YCharts.

Illumina published preliminary first-quarter results on April 5, indicating that it expected revenue of $1.085 billion in the quarter. The average analyst estimate called for $924.6 million in sales in the period. The company also announced that it expected orders in the quarter to be up 28%, reaching a record $1.4 billion.

Illumina has a market capitalization of roughly $60.5 billion and is valued at approximately 15 times this year's expected sales and 78 times expected earnings. 

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Barclays. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina Stock Quote
$220.03 (0.89%) $1.95
Barclays Stock Quote
$158.28 (-1.84%) $-2.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.